Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Brenda Burnham"'
Autor:
Laura P. van Lieshout, Miranda Rubin, Katrina Costa-Grant, Stacy Ota, Diane Golebiowski, Troy Panico, Eli Wiberg, Klaudia Szymczak, Richard Gilmore, Marissa Stanvick, Brenda Burnham, Jeff Gagnon, Ifeyinwa Iwuchukwu, Guang Yang, Iraj Ghazi, Alex Meola, Ryan Dickerson, Thomas Thiers, Luke Mustich, April Hayes, Israel Rivas, Jason Lotterhand, Nancy Avila, James McGivney, Jin Yin, Tim Kelly
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 29, Iss , Pp 426-436 (2023)
Transient transfection of mammalian cells using plasmid DNA is a standard method to produce adeno-associated virus (AAV) vectors allowing for flexible and scalable manufacture. Typically, three plasmids are used to encode the necessary components to
Externí odkaz:
https://doaj.org/article/25fd1b8281394ec9b15853de27025cb5
Autor:
Sirkka Kyostio-Moore, Patricia Berthelette, Susan Piraino, Cathleen Sookdeo, Bindu Nambiar, Robert Jackson, Brenda Burnham, Catherine R O'Riordan, Seng H Cheng, Donna Armentano
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Recombinant adeno-associated viral (rAAV) vectors containing oversized genomes provide transgene expression despite low efficiency packaging of complete genomes. Here, we characterized the properties of oversized rAAV2/8 vectors (up to 5.4 kb) encodi
Externí odkaz:
https://doaj.org/article/dc83fa3e7b174a09885970c39aa9a954
Autor:
Maryellen Mattingly, Denise Woodcock, Jeffery Ardinger, Shelley Nass, Seng H. Cheng, Brenda Burnham, Catherine R. O'Riordan, Shayla E. Osmond, Amy Frederick, Abraham Scaria
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 9, Iss, Pp 33-46 (2018)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
The generation of clinical good manufacturing practices (GMP)-grade adeno-associated virus (AAV) vectors requires purification strategies that support the generation of vectors of high purity, and that exhibit a good safety and efficacy profile. To d
Autor:
Brenda Burnham, Abraham Scaria, Samuel C. Wadsworth, Seng H. Cheng, Denise Woodcock, Catherine R. O'Riordan, Elton Kong, Antonius Song, Maryellen Mattingly, Shelley Nass
Publikováno v:
Human Gene Therapy Methods. 26:228-242
Recombinant adeno-associated viral (rAAV) vectors represent a novel class of biopharmaceutical drugs. The production of clinical-grade rAAV vectors for gene therapy would benefit from analytical methods that are able to monitor drug product quality w
Autor:
Patricia Berthelette, Bindu Nambiar, Donna Armentano, Cathleen Sookdeo, Brenda Burnham, Susan Piraino, Sirkka Kyostio-Moore, Shelley Nass, Karen A. Vincent, Seng H. Cheng, Catherine R. O'Riordan, David W. Souza, Robert B. Jackson
Publikováno v:
Human gene therapy methods. 28(1)
Several ongoing clinical studies are evaluating recombinant adeno-associated virus (rAAV) vectors as gene delivery vehicles for a variety of diseases. However, the production of vectors with genomes >4.7 kb is challenging, with vector preparations fr
Autor:
Denise Woodcock, Tony Song, Abraham Scaria, Elton Kong, Shelley Nass, Maryellen Mattingly, Brenda Burnham, Catherine R. O'Riordan, Seng H. Cheng
Publikováno v:
Molecular Therapy. 23
Appropriately engineered recombinant adeno-associated viral (rAAV) vectors represent a novel class of biopharmaceutical drugs. The production of clinical-grade rAAV vectors for gene therapy would benefit from analytical methods that are able to monit
Autor:
Sirkka Kyostio-Moore, Susan Piraino, Patricia Berthelette, Bindu Nambiar, Cathleen Sookdeo, Seng H. Cheng, Armentano Donna, Catherine R. O'Riordan, Brenda Burnham, Robert B. Jackson
Publikováno v:
Molecular Therapy. 23
Severe hemophilia A patients with 4 years and consequent reduction or elimination of the need for frequent factor infusions. Similar rAAV-mediated gene transfer for hemophilia A patients is challenging due to the size of the FVIII cDNA that when comb
Autor:
Donna Armentano, Sirkka Kyostio-Moore, Catherine R. O'Riordan, Robert B. Jackson, Cathleen Sookdeo, Seng H. Cheng, David W. Souza, Shelley Nass, Karen A. Vincent, Brenda Burnham, Patricia Berthelette, Bindu Nambiar
Publikováno v:
Molecular Therapy. 24:S40
Recombinant adeno-associated virus (rAAV) vectors are being evaluated as gene delivery vehicles in several clinical trials. The 4.7 kb wild-type (WT) size genome of AAV presents a challenge for incorporating larger transgenes with incomplete vector g
Autor:
Susan Piraino, Robert Jackson, Seng H. Cheng, Donna Armentano, Brenda Burnham, Sirkka Kyostio-Moore, Catherine R. O'Riordan, Cathleen Sookdeo, Patricia Berthelette, Bindu Nambiar
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Recombinant adeno-associated viral (rAAV) vectors containing oversized genomes provide transgene expression despite low efficiency packaging of complete genomes. Here, we characterized the properties of oversized rAAV2/8 vectors (up to 5.4 kb) encodi
Publikováno v:
Molecular Reproduction and Development. 34:164-174
The presence of lamin proteins in mouse spermatogenic cells has been examined by using an anti-lamin AC and an anti-lamin B antisera which recognize somatic lamins A and C, and somatic lamin B, respectively. Anti-lamin B binds to the nuclear peripher